Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.
29 October 2021

Vator Securities advises SenzaGen on 30 MSEK Directed Share Issue

About SenzaGen

SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings. The company´s state-of-the-art GARD® test platform combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. Its high informational content and a holistic view of the immunological responses contribute to high predictive accuracy and human relevance. SenzaGen has its headquarters and GLP certified laboratory in Lund, Sweden, and a subsidiary in the US.

Press release

The case

  • Targeting category leadership within non-animal testing through continued execution upon the accelerated growth strategy involving acquisitions and rapid organic growth.
  • Genomics, machine learning and biology is combined in the company’s GARD®-platform, resulting in accuracy of over 90%, ability to handle challenging samples in small quantities and with short turn-around time.
  • The positive EURL ECVAM evaluation of GARD®skin significantly increases OECD’s likelihood of final approval, enabling SenzaGen to offer the GARD® technology to a significantly broader customer base, further expanding the market potential.